Reading BCRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BCRX free→Reading BCRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BCRX free→QuarterlyIQ Insights · BCRX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amended and Restated Stock Incentive Plan On June 11, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Company’s stockholders approved, by the affirmative vote of a majority of the shares of the Company’s common stock represented in person or by pr…
Results of Operations and Financial Condition. On May 6, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the first quarter ended March 31, 2026, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Results of Operations and Financial Condition. On February 26, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the fourth quarter and full year ended December 31, 2025, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Entry Into a Material Definitive Agreement. On January 23, 2026 (the “ Closing Date ”), BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ”), entered into a Loan Agreement (the “ Loan Agreement ”), by and among BioCryst, as borrower, the guarantors from time to time party thereto, Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C., as the Blackstone representatives thereunder, the lenders from time to time party thereto and Wilmington Trust…
Completion of Acquisition or Disposition of Assets. On the Closing Date, BioCryst completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025 (the “ Merger Agreement ”), by and among BioCryst, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst (“ Merger Sub ”), and Astria Therapeutics, Inc., a Delaware corporation (“ Astria ”). On the Closing Date, Merger Sub merged with and into Astria (the “ Merger ”), with A…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 23, 2026 (the “ Closing Date ”), BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ”) completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025 (the “ Merger Agreement ”), by and among BioCryst, Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of…
Results of Operations and Financial Condition. On January 12, 2026, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release (the “Press Release”) announcing, among other things, preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year ended December 31, 2025. The Company also provided guidance for full year 2026 ORLADEYO net revenue, total revenue, and operating expenses. The Press Release also referenced a previously announced, upcoming w…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 9, 2025, Nancy J. Hutson, Ph.D. notified BioCryst Pharmaceuticals, Inc. (the “Company”) of her intention to retire from the Board of Directors of the Company (the “Board”), effective as of the earlier of (i) the closing date of the previously announced proposed acquisition of Astria Therapeutics, Inc. and (ii) the date of the Company’s…
Other Events. On December 3, 2025, BioCryst Pharmaceuticals, Inc. (“BioCryst”) issued a press release announcing early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), with respect to its previously announced proposed acquisition (the “Merger”) of Astria Therapeutics, Inc. (“Astria”). A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Termination of the waiting per…
Results of Operations and Financial Condition. On November 3, 2025, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the third quarter ended September 30, 2025, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Other Events. On October 8, 2025, BioCryst paid off in full and terminated that certain Loan Agreement, dated as of April 17, 2023, among BioCryst, the other guarantors from time to time party thereto, BioPharma Credit PLC, as collateral agent, and BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP, as lenders (as amended, restated, amended and restated, supplemented or otherwise modified from time to time). On October 14, 2025, BioCryst and Astria issued a joint press re…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 13, 2025, subject to certain conditions specified in the Merger Agreement (including the occurrence of the Effective Time), BioCryst’s board of directors (the “ BioCryst Board ”) approved an increase in the size of the BioCryst Board and elected Jill C. Milne, Ph.D., President, Chief Executive Officer and member of the board of directors…
Entry into a Material Definitive Agreement. Agreement and Plan of Merger On October 14, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ”), Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst (“ Merger Sub ”), and Astria Therapeutics, Inc., a Delaware corporation (“ Astria ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the co…
of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by BioCryst under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Entry into a Material Definitive Agreement In connection with the Transaction, on October 1, 2025, the Company and BioCryst Ireland amended and restated that certain IP Licence Agreement by and between the Company and BioCryst Ireland, dated as of May 13, 2021 (such amended and restated agreement, the “ Amended and Restated IP Licence Agreement ”). Pursuant to the Amended and Restated IP Licence Agreement, the Company granted to BioCryst Ireland an exclusive license under certain patents, sol…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 6, 2025, Dr. Helen Thackray, Chief Research and Development Officer of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), notified the Company of her intention to resign from her role as Chief Research and Development Officer of the Company, effective September 1, 2025 (the “Effective Date”). After participating in th…
Results of Operations and Financial Condition. On August 4, 2025, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the second quarter ended June 30, 2025, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Retirement of Chief Executive Officer On July 25, 2025, Jon Stonehouse, President and Chief Executive Officer of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), notified the Company’s Board of Directors (the “Board”) of his intention to retire from his role as President and Chief Executive Officer of the Company, effective D…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 7, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), announced the appointment of Babar Ghias, age 46, as Chief Financial Officer of the Company, effective as of July 7, 2025, and as approved by the Company’s Board of Directors (the “Board”) on June 11, 2025. Mr. Ghias will also serve as the Company’s Principal A…
Entry into a Material Definitive Agreement. On June 27, 2025, BioCryst Pharmaceuticals, Inc., a Delaware corporation (“ BioCryst ” or the “ Company ”), and BioCryst Ireland Limited (“ BioCryst Ireland ”), a private limited company incorporated under the laws of Ireland and a wholly owned subsidiary of the Company, entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with Neopharmed Gentili S.p.A., a corporation organized under the laws of Italy (the “ Purchaser ”). Under the t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Director On June 11, 2025, George B. Abercrombie notified BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), of his intention to retire from the Board of Directors of the Company (the “Board”), effective as of the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Prior to his retirement, Mr. Abe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously announced, the Compensation Committee of the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) approved a Consulting Agreement with Anthony Doyle, the Company’s former Chief Financial Officer, effective April 9, 2025, pursuant to which Mr. Doyle provides transition services to the Company in exchange for a $450 hour…
Results of Operations and Financial Condition. On May 5, 2025, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the first quarter ended March 31, 2025, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 30, 2025, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) approved an increase in the size of the Board from ten to eleven directors and elected Steven Frank to fill the vacancy created by the enlargement of the Board, effective May 2, 2025 (the “Effective Date”). Mr. Frank’s initial term will expire…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.